Evogene Sharpened Focus on AI-Driven Molecule Design Drives Cost Cuts
Event summary
- Evogene underwent a strategic shift in 2025, concentrating on its ChemPass AI™ platform for small-molecule discovery and optimization.
- The company discontinued non-core activities, divested subsidiaries Lavie Bio (acquired by ICL) and Biomica (licensed assets to Lishan Pharmaceuticals), and resized its organization.
- Evogene collaborated with Google Cloud, achieving a 90% design precision benchmark with a foundation model trained on 38 billion structures.
- Operating expenses decreased significantly, from $22.0 million in 2024 to approximately $13.8 million in 2025, driven by the restructuring and divestitures.
- Revenues decreased from $5.6 million in 2024 to $3.9 million in 2025, primarily due to reduced activity from AgPlenus and Casterra.
The big picture
Evogene's strategic pivot reflects a broader trend in the biotech and ag-tech sectors towards specialization and leveraging AI to accelerate discovery and reduce R&D costs. The company's decision to divest non-core assets and focus on ChemPass AI™ represents a bet on generative AI's ability to disrupt traditional molecule design processes. The success of this strategy will depend on Evogene's ability to secure and execute partnerships, and demonstrate a clear return on investment from its concentrated efforts.
What we're watching
- Commercial Traction
- The success of Evogene's focused strategy hinges on the ability to translate ChemPass AI™ into commercially viable drug and agricultural product candidates, and the pace at which these collaborations yield revenue.
- Google Dependency
- Evogene's reliance on Google Cloud for AI infrastructure and development poses a risk if the partnership weakens or costs increase.
- Casterra Performance
- The performance of Casterra’s Brazilian operations will be critical to demonstrating the viability of the retained activities and offsetting the impact of the Kenya shutdown.
Related topics